Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 3/20 | 0.31 |
| ▸ | GPR39 | O43194 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28561616 | 0.93 | KMT2A (0.40) | HTR1ADRD2DRD4KCNH2SCN5A | |
| SCHEMBL21285293 | 0.76 | TYK2 (0.48) | HTR1ADRD2DRD4KCNH2SCN5A | |
| SCHEMBL20688191 | 0.76 | TYK2 (0.48) | HTR1ADRD2DRD4KCNH2SCN5A | |
| SCHEMBL20688224 | 0.76 | TYK2 (0.48) | HTR1ADRD2DRD4KCNH2SCN5A | |
| SCHEMBL19923231 | 0.76 | CYP1A2 (0.40) | NCF1GPR39 | |
| SCHEMBL1854614 | 0.76 | CCR1 (0.46) | HTR1ADRD2DRD4KCNH2KMT2A | |
| SCHEMBL28140219 | 0.76 | HTR1A (0.47) | HTR1ADRD2DRD4KCNH2SCN5A | |
| SCHEMBL22023266 | 0.74 | HPGD (0.66) | HTR1ADRD2DRD4HPGD | |
| Hydrochloric Acid SCHEMBL28521485 | 0.74 | HTR1A (0.46) | HTR1ADRD2DRD4KCNH2SCN5A | |
| SCHEMBL7029297 | 0.74 | NSD2 (0.33) | NSD2CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349896-B | Heterocyclic compounds as FGFR inhibitors | 南京天印健华医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-107667092-B | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | 诺华股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-10590109-B2 | Heterocyclic compounds used as FGFR inhibitors | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-03-17 | — | — | US | disclosed |
| US-10590109-B2 | Heterocyclic compounds used as FGFR inhibitors | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-03-17 | — | — | US | disclosed |
| EP-3489223-A1 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR | Nanjing Innocare Pharma Tech Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| US-20190144427-A1 | HETEROCYCLIC COMPOUNDS USED AS FGFR INHIBITORS | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-05-16 | — | — | US | disclosed |
| US-20190144427-A1 | HETEROCYCLIC COMPOUNDS USED AS FGFR INHIBITORS | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-05-16 | — | — | US | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144427-A1 | HETEROCYCLIC COMPOUNDS USED AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | HTR1A 3766/4885DRD2 4695/4885DRD4 4864/4885 |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | FGFR4, FGFR1, FGFR3 | HTR1A 3053/4885DRD2 4129/4885DRD4 3698/4885 |
| US-10590109-B2 | Heterocyclic compounds used as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | HTR1A 3766/4885DRD2 4695/4885DRD4 4864/4885 |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | HTR1A 3082/4885DRD2 3991/4885DRD4 3615/4885 |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | HTR1A 3082/4885DRD2 3991/4885DRD4 3615/4885 |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | HTR1A 3082/4885DRD2 3991/4885DRD4 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.